Paysign Earnings Call Transcripts
Fiscal Year 2026
-
Strong revenue and EBITDA growth driven by both plasma and patient affordability businesses, with proprietary technology providing a competitive edge and significant cost savings for clients. Market leadership, regulatory compliance, and a scalable platform position the company for continued expansion.
-
A leading provider of plasma donor payments and pharma co-pay solutions, the company is experiencing rapid growth in its patient affordability business, driving margin expansion and a shift in revenue mix. Proprietary technology and regulatory compliance underpin its competitive edge.
-
Record Q1 results with revenue up 50.8% and net income up 110% year-over-year, driven by strong growth in patient affordability and plasma segments. Guidance raised for 2026, with robust pipelines and no expected impact from plasma center closures.
Fiscal Year 2025
-
Revenue grew 40.5% to $82M in 2025, with net income up 98% and strong margin expansion. Patient Affordability revenue surged 168%, and 2026 guidance calls for 30–35% growth, driven by both plasma and pharma segments.
-
Leadership with deep payments and banking expertise drives growth in patient affordability and plasma payment sectors. Proprietary technology and high client retention fuel strong financial performance, with revenue and margins rising year-over-year.
-
Q3 2025 saw record revenue and profit growth, led by a 142% surge in patient affordability revenue and continued expansion in plasma. Guidance for 2025 was raised, with strong margin improvements and robust cash flow, despite plasma industry oversupply and regulatory delays for new tech platforms.
-
Record Q2 revenue rose 33% to $19.1M, driven by 190% growth in patient affordability, while plasma revenue declined 4.7% year-over-year but rebounded sequentially. 2025 guidance was raised, with strong margin expansion and robust program pipeline supporting continued growth.
-
Paysign highlighted strong revenue growth, especially in patient affordability, and improved margins driven by technology and strategic acquisitions. Plasma business faces short-term headwinds, but investments and new software are expected to drive future growth.
-
Record Q1 2025 results with 41% revenue growth and 737% net income increase, driven by strong Patient Affordability performance. Plasma segment declined, but guidance for 2025 was raised, reflecting robust outlook and operational efficiencies from the Gamma acquisition.
Fiscal Year 2024
-
Revenue grew 23.5% in 2024, driven by 212% growth in patient affordability, while plasma revenue rose 4.6% despite Q4 headwinds. 2025 guidance projects 17.5%-20% revenue growth, with pharma expected to double and plasma to remain challenged.
-
Revenue grew 23% year-over-year to $15.3M, driven by 219% growth in patient affordability, which now represents over 21% of total revenue. Gross margin improved to 55.5%, and full-year guidance remains strong despite legal expenses and plasma business headwinds.
-
A healthcare-focused prepaid card provider reported strong revenue growth, especially in its patient affordability business, which is expected to surpass plasma payments in the coming years. The company maintains a debt-free balance sheet, robust margins, and is pursuing shareholder returns through share repurchases.
-
Q2 2024 saw revenue rise 30% year-over-year to $14.3M, driven by 267% growth in patient affordability and solid plasma business gains. Gross margin improved 200 bps, and full-year guidance was raised, with net income forecast at $2–3M and Adjusted EBITDA at $9–10M.
-
A leading provider of prepaid payment solutions, especially in healthcare, reported strong revenue growth and expanding market share in plasma and patient affordability programs. End-to-end in-house operations, proprietary technology, and transparent pricing drive differentiation and client retention.